Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CTH522 Vaccine
NCT03926728Phase 1Completed
- Sponsor
- Statens Serum Institut
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CTH522 in trachoma and chlamydia infection (6 cohorts), sponsored by Statens Serum Institut. Primary endpoints: Solicited Local Injection Site Reactions at Day 126, Solicited Local Ocular Reactions at Day 154 and 1 more. Started Feb 2020; status: completed.
02
Drugs
CTH522
03
Conditions
trachomachlamydia infection
Beyond the preview
Go deeper on NCT03926728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926728.